Abstract
Seventeen out of 20 inactive and emotionally withdrawn schizophrenic patients under long-term neuroleptic treatment completed a double-blind cross-over investigation of the possible activating effect of maprotiline, a relatively specific noradrenaline-reuptake inhibitor, compared with that of placebo. Each treatment phase lasted 8 weeks. No significant differences with respect to either the level of activity or schizophrenic symptoms were found between maprotiline (mean dose 138 mg/day) and placebo. Maprotiline provoked a slight psychotic exacerbation in one patient and sedation in another, four patients developed orthostatic hypotension, and two patients had an epileptic seizure. In the light of this and other studies, it must be concluded that antidepressant drugs do not represent any therapeutic advance in the treatment of inactive schizophrenic patients receiving neuroleptics.
References
Oct 14, 1975·Psychopharmacologia·J Gerlach, K Lühdorf
Sep 1, 1978·Archives of General Psychiatry·T Van Putten, R P May
Nov 1, 1978·Archives of General Psychiatry·S G SirisJ P Docherty
Oct 1, 1979·Psychopharmacology·B VandelR Volmat
Sep 30, 1978·British Medical Journal·M J Hall, R I Russell
Jan 1, 1978·The Journal of International Medical Research·A Delini-StulaA Vassout
Jan 1, 1979·The Journal of International Medical Research·P A Baumann, L Maître
Jan 7, 1978·British Medical Journal
Sep 1, 1974·Acta Pharmacologica Et Toxicologica·L F GramK F Overo
Jul 4, 1973·Psychopharmacologia·B AngristS Gershon
Jan 1, 1974·Acta Psychiatrica Scandinavica. Supplementum·Z CesarecL Nordgren
Jan 1, 1957·The Journal of Mental Science·P H VENABLES
Jan 1, 1965·Journal of Clinical Psychology·G HONIGFELD, C J KLETT
Citations
Jan 1, 1981·Psychopharmacology·S KorsgaardJ Gerlach
Jan 1, 1989·The Psychiatric Quarterly·S J Bartels, R E Drake
Feb 1, 1995·Psychopharmacology·D C GoffE Amico
Sep 1, 2004·Psychopharmacology·B PouzetS Hogg
Jan 1, 1991·Progress in Neuro-psychopharmacology & Biological Psychiatry·S G SirisM A Shuwall
Mar 1, 1991·Pharmacopsychiatry·D Naber, H Hippius
Jun 5, 1998·Biological Psychiatry·G D TollefsonP V Tran
Jan 19, 2002·Journal of Clinical Psychopharmacology·Donald AddingtonLinda Beauclair
Aug 19, 2003·CNS Drugs·Hans-Jürgen Möller
Sep 3, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Surendra P SinghKelvin Chan
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Prakash S MasandAshwin A Patkar
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Nov 8, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Hans-Jürgen Möller
Mar 3, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Sep 27, 2005·Schizophrenia Research·Christine RummelStefan Leucht
May 21, 2015·The International Journal of Neuropsychopharmacology·Viacheslav TerevnikovJan-Henry Stenberg
Jun 22, 2002·The Cochrane Database of Systematic Reviews·C WhiteheadG Lewis